Announced today that Bristol-Myers Squibb has acquired iPierian.

The transaction is expected to become accounted for as a secured asset acquisition for Bristol-Myers Squibb producing a $175 million charge during the second quarter of 2014. ‘As part of our development to a diversified specialty BioPharma firm, we’ve identified genetically defined diseases as a location where the company has an opportunity to significantly advance the typical of care for sufferers with limited treatment plans,’ said Francis Cuss, executive vice president and chief scientific officer, Bristol-Myers Squibb. ‘The acquisition of iPierian supports our growing efforts in this region and builds on Bristol-Myers Squibb's inner alliances and expertise centered on the Tau pathway and neurodegenerative diseases.’ Related StoriesResearchers successfully restoration nerve cell damage in Alzheimer's dementiaInner ear damage human brain warnings from nerve cellsRice scientists solve long-standing up mystery regarding hemophilia protein ‘iPierian's discovery of a novel system of secreted Tau biology was the foundation of the IPN007 program,’ said Dr.An interview with Dr Matt SilverHSS experts help identify lupus patients at increased risk of problem pregnanciesAntibiotics haven’t any adverse outcome on kid's physical development, displays studyAhead of the global world Economic Forum, Reuters examines the economic opportunities and challenges for traders in Africa. Nevertheless, ‘the International Monetary Fund believes development in sub-Saharan Africa will become 1 %age stage above the global typical, and puts eight African countries in its best 20 fastest-expanding economies this year 2010’ .